Edecrin

induction of Diuresis, Nephrotic Syndrome, Ascites + 5 more
Treatment
11 FDA approvals
20 Active Studies for Edecrin

What is Edecrin

Etacrynic acidThe Generic name of this drug
Treatment SummaryThis drug is a diuretic that helps rid the body of excess salt and water. It works by blocking the absorption of sodium, potassium, and chloride in the kidneys, which causes more of these ions to be excreted in the urine and results in increased urinary output. This drug is known as a “loop diuretic” or “high ceiling diuretic” and is often prescribed to treat conditions such as edema and high blood pressure.
Ethacrynic Acidis the brand name
Edecrin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ethacrynic Acid
Etacrynic acid
1967
28

Approved as Treatment by the FDA

Etacrynic acid, otherwise called Ethacrynic Acid, is approved by the FDA for 11 uses including Congestive Heart Failure (CHF) and Congenital Heart Disease (CHD) .
Congestive Heart Failure (CHF)
Congenital Heart Disease (CHD)
Helps manage Congenital Heart Disease (CHD)
Cirrhosis of the Liver
Edema
Ascites
Helps manage Ascites
Nephrotic Syndrome
Cirrhosis
Congenital Heart Defect
Helps manage Congenital Heart Disease (CHD)
Ascites
Helps manage Ascites
Swollen feet or ankles
Congestive Heart Failure

Effectiveness

How Edecrin Affects PatientsEthacrynic acid is a type of diuretic, which means it helps the body get rid of extra fluid. It does this by blocking sodium from being reabsorbed by the kidneys, so it can be passed out of the body. This drug is very effective in people with kidney problems, as it can help them get rid of excess fluid. Unlike other diuretics, ethacrynic acid doesn't affect how well the kidneys filter or how much blood flows to them, except when the patient has lost a lot of fluid quickly.
How Edecrin works in the bodyEthacrynic acid works as a diuretic to reduce blood pressure. It achieves this by preventing sodium, potassium, and chloride from being absorbed into the body, and instead causes them to be flushed out with urine. This leads to a decrease in plasma and extracellular fluid, which lowers both blood pressure and cardiac output. It works in a different way than carbonic anhydrase inhibitors.

When to interrupt dosage

The proposed dosage of Edecrin is reliant upon the diagnosed condition, such as Swelling, Cirrhosis and Ascites. The measure of dosage shifts with the technique of delivery (e.g. Tablet or Powder, for solution - Intravenous) featured in the table beneath.
Condition
Dosage
Administration
induction of Diuresis
25.0 mg, , 5.0 mg/mL, 50.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Nephrotic Syndrome
25.0 mg, , 5.0 mg/mL, 50.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Ascites
25.0 mg, , 5.0 mg/mL, 50.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Swollen feet or ankles
25.0 mg, , 5.0 mg/mL, 50.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Cirrhosis
25.0 mg, , 5.0 mg/mL, 50.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Congenital Heart Defect
25.0 mg, , 5.0 mg/mL, 50.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Diuresis
25.0 mg, , 5.0 mg/mL, 50.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous
Congestive Heart Failure
25.0 mg, , 5.0 mg/mL, 50.0 mg
, Oral, Tablet, Tablet - Oral, Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous

Warnings

There are 20 known major drug interactions with Edecrin.
Common Edecrin Drug Interactions
Drug Name
Risk Level
Description
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Etacrynic acid is combined with Neomycin.
Tenofovir
Major
Etacrynic acid may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Etacrynic acid may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir disoproxil
Major
Etacrynic acid may increase the nephrotoxic activities of Tenofovir disoproxil.
Acebutolol
Minor
The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acebutolol.
Edecrin Toxicity & Overdose RiskTaking too much of this drug can cause excessive urination, leading to loss of important minerals and salts from the body.
image of a doctor in a lab doing drug, clinical research

Edecrin Novel Uses: Which Conditions Have a Clinical Trial Featuring Edecrin?

166 active clinical trials are currently underway to assess the potential of Edecrin in treating Nephrotic Syndrome, Ascites and Cirrhosis.
Condition
Clinical Trials
Trial Phases
Cirrhosis
52 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1
Nephrotic Syndrome
5 Actively Recruiting
Phase 2, Not Applicable, Phase 3
Diuresis
0 Actively Recruiting
induction of Diuresis
0 Actively Recruiting
Ascites
2 Actively Recruiting
Not Applicable, Phase 2
Congenital Heart Defect
27 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 1
Congestive Heart Failure
11 Actively Recruiting
Not Applicable, Phase 1, Phase 2
Swollen feet or ankles
5 Actively Recruiting
Phase 2, Not Applicable, Phase 4

Edecrin Reviews: What are patients saying about Edecrin?

5Patient Review
1/21/2009
Edecrin for Visible Water Retention
Quickly and effectively removed the fluid retention in my right leg caused by amlodipine.
4.3Patient Review
11/21/2013
Edecrin for High Blood Pressure
I have an allergy to sulfa drugs, so this is the only water pill I can take. It works well for me. When I run out and have to wait to get more, my blood pressure goes up significantly.
4Patient Review
6/25/2012
Edecrin for High Blood Pressure
I've been on this medication for two months and it's been working well so far. I'm allergic to sulfa, and was previously taking bystolic; however, I had to stop because it made me sick. Make sure to check for sulfites in everything if you're also allergic.
4Patient Review
8/3/2012
Edecrin for Visible Water Retention
I would appreciate learning more about the manufacturer of this drug, Draxis.
3.7Patient Review
3/12/2008
Edecrin for Visible Water Retention
2.7Patient Review
1/1/2018
Edecrin for Visible Water Retention
Whenever I took Edecrin, I would begin vomiting, have severe watery diarrhea, and feel weak and achy. This made it impossible for me to work. Since I'm allergic to sulfa, I don't know what my next course of action will be.
2.7Patient Review
12/29/2013
Edecrin for High Blood Pressure
I started taking this medication to help lower my blood pressure in 2013. Last November, I started vomiting frequently and realized that it was likely due to the Edecrin. Since stopping the medication, I feel great!
2.3Patient Review
7/24/2010
Edecrin for Visible Water Retention
I took this medicine because I had a severe allergic reaction to lasix. This drug does not have sulfa. However, I had severe migraines while on this medication as well as itching and developed red pimples. Did not find this drug effective in aiding in eliminating water retention. Did assist in lowering bp a little. Stopped taking several times to confirm it was this medication causing the side effects and not bystolic which I am also on
2.3Patient Review
9/20/2010
Edecrin for High Blood Pressure
I had been managing my acid reflux well before starting this medication 3 weeks ago, but since then it's been much worse.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about edecrin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of diuretic is Edecrin?

"Ethacrynic acid works as a loop diuretic in the kidney to remove certain electrolytes and extra fluid from your body in order to lower swelling."

Answered by AI

What is Edecrin used for?

"This medication is used to decrease swelling that is caused by conditions such as cancer, congestive heart failure, liver disease, and kidney disease. This effect can help improve kidney function and lessen symptoms such as trouble breathing and swelling in the ankles, feet, hands, or stomach."

Answered by AI

Is Edecrin ototoxic?

"Some patients experience permanent hearing loss as a result of taking EDECRIN, especially those also taking other ototoxic drugs. Ototoxic drugs are known to increase the potential for hearing loss (see Drug Interactions in the precautions section)."

Answered by AI

Is Edecrin a loop diuretic?

"Edecrin is a loop diuretic used to treat fluid retention in people with congestive heart failure, liver disease, or a kidney disorder such as nephrotic syndrome."

Answered by AI

Clinical Trials for Edecrin

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

AI-Enabled Identification for Fatty Liver Disease

18+
All Sexes
Los Angeles, CA
The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction associated steatotic liver disease (MASLD) and/or cirrhosis, in patients undergoing routine transthoracic echocardiograms (TTEs). The main question it aims to answer is to: 1. Evaluate notification responsiveness and rates of confirmatory testing for patients identified as high risk for having liver disease to determine whether optimized notifications increase timely confirmatory testing and treatment initiation versus standard of care assessment. 2. Compare time to diagnosis, treatment uptake, and clinical outcomes (hospitalizations, incident ASCVD, mortality) between cohorts identified as high risk by the AI algorithm and comparison groups to determine whether AI guided screening shortens time to diagnosis and increases appropriate treatment.
Waitlist Available
Has No Placebo
Cedars-Sinai Medical Center (+3 Sites)
Image of Cleveland Clinic Main Campus in Cleveland, United States.

Metabolic Surgery and TIPS for Liver Cirrhosis

18 - 70
All Sexes
Cleveland, OH
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver. CSPH raises the risk of life-threatening events like internal bleeding and liver failure. Unfortunately, treatment options for people who have both cirrhosis and severe obesity are very limited, especially when portal hypertension is present. This study, called the OPTIMAL Trial, is a randomized clinical trial designed to evaluate whether combining two procedures improves health outcomes in this high-risk population. The first procedure, called TIPS (Transjugular Intrahepatic Portosystemic Shunt), is a minimally invasive treatment that reduces pressure in the liver by creating a pathway for blood to flow more easily. The second procedure is sleeve gastrectomy, a form of metabolic (bariatric) surgery that helps patients lose weight and improve related conditions like diabetes. The study will compare two groups: 1. One group will receive TIPS followed by sleeve gastrectomy (TIPS+SG). 2. The other group will receive medical weight management (standard non-surgical care, including diet, lifestyle changes, and weight loss medications). All participants will have severe obesity and cirrhosis with CSPH but will not have decompensated liver disease (such as large amounts of fluid in the abdomen, a history of variceal bleeding, or recent liver failure). Eligible participants will be randomly assigned to one of the two groups. The main goal of the study is to determine whether the combination of TIPS + SG improves quality of life and leads to greater weight loss compared to medical therapy alone. The study will also monitor for any complications from either the procedures or the medical treatment. Participants will be followed for 6 months after their treatment starts, with periodic assessments of their physical health, liver function, and overall well-being. Some participants may also be followed for a longer period to assess long-term outcomes. This study hopes to provide high-quality evidence for a novel, stepwise treatment strategy that may help people with obesity and liver disease live longer, healthier lives. If successful, it could change how advanced liver disease and obesity are managed together, especially in patients who currently have few safe and effective options. All study care is provided at Cleveland Clinic, Cleveland, Ohio, USA.
Phase 4
Recruiting
Cleveland Clinic Main CampusSobia Laique, MD
Image of NewYork-Presbyterian/Weill Cornell Medical Center in New York, United States.

Melatonin for Liver Cirrhosis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn the affect of melatonin on sleep, cognitive function, and quality of life (QoL) in patients with cirrhosis and a complication called hepatic encephalopathy (HE). The main questions this study aims to answer are: * Does taking melatonin increase REM sleep, an important part of healthy sleep that is reduced in cirrhosis? * Does taking melatonin improve cognitive function and reported QoL? This is a pilot study, where participants will: * take one month of melatonin, followed by one month of thiamine, which is another supplement but is not suspected to impact sleep significantly. * Undergo cognitive testing and take surveys * Wear a commercial wearable sleep tracker * Have a formal sleep study and salivary melatonin collection at the end of taking each supplement at our sleep center Participants will be blinded, and neither they nor the researchers will know which supplement they are taking first and which they are taking second. They will also be randomized, with half starting with melatonin and the other half starting with thiamine.
Recruiting
Has No Placebo
NewYork-Presbyterian/Weill Cornell Medical CenterAdam Buckholz, MD MS
Have you considered Edecrin clinical trials? We made a collection of clinical trials featuring Edecrin, we think they might fit your search criteria.Go to Trials
Image of Children's Hospital Los Angeles in Los Angeles, United States.

Parent Navigator Program for Congenital Heart Disease

Any Age
All Sexes
Los Angeles, CA
The goal of this clinical trial is to see if a Parent Navigator Program (PNP) is helpful for Latino/x parents of babies with congenital heart disease (CHD) to get connected to developmental follow-up services. The main question it aims to answer are: * Do families assigned to the Parent Navigator Program (PNP) have higher rates of connection to High-Risk Infant Follow-Up (HRIF)/Early Intervention (EI) compared to the standard care group 6 months after randomization? * Do children assigned to the Parent Navigator Program (PNP) have better neurodevelopmental outcomes (NDOs) compared to the standard care group 6 months after randomization? * Do parents assigned to the Parent Navigator Program (PNP) have decreased parental stress compared to the standard care group? Researchers will compare the Parent Navigator group to the standard care group to see if parent navigator group is helpful in connecting families to High-Risk Infant Follow-Up (HRIF)/Early Intervention (EI), improving neurodevelopmental outcomes (NDOs), and lowering parental stress. Participants will: * Undergo developmental assessments and survey at newborn stage and at 6 months * Participants randomly assigned to the Parent Navigator group will have weekly (at least) phone calls with the parent navigator * Participants randomly assigned to the Parent Navigator group will complete a 30-minute phone interview about their experience with the parent navigator program 6 months after random assignment
Recruiting
Has No Placebo
Children's Hospital Los AngelesNhu Tran, PhD, RN
Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA
Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.
Waitlist Available
Has No Placebo
Virginia Commonwealth UniversityAarti Sarwal
Image of Future Life Clinical Trials in Miami, United States.

Extended vs Immediate Release Torsemide for Heart Failure

18+
All Sexes
Miami, FL
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide. This is a randomized, double-blind, crossover study in patients with heart failure who are on a stable dose of a loop diuretic. During the study period, participants' current loop diuretics will be replaced with an equivalent dose of either immediate-release or extended-release torsemide. Following a one-week stabilization period on the assigned torsemide formulation, patients will report to the clinical site for an assessment visit. On the study day, patients will take a single dose of the same torsemide formulation they have been on for the past week, administered after breakfast. Urine samples be collected are: * 0-4 hours post-dosing (pre-lunch period) * 4-8 hours post-dosing (post-lunch period) * 8-24 hours post-dosing (24 hours period) The primary endpoint will be urinary sodium excretion (4-8 hours after dosing). This will be compared between the extended-release arm and the immediate-release arm to assess the efficacy of prolonged diuretic action. In addition, urinary potassium and creatinine excretion and creatinine clearance will be measured in all urine samples as the safety endpoints.
Phase 4
Recruiting
Future Life Clinical TrialsSalim Shah, PhD, JDSarfez Pharmaceuticals, Inc.
Have you considered Edecrin clinical trials? We made a collection of clinical trials featuring Edecrin, we think they might fit your search criteria.Go to Trials
Image of University Health Network in Toronto, Canada.

Empagliflozin for Congenital Heart Disease

18+
All Sexes
Toronto, Canada
Some people are born with a birth defect where they only have one functioning ventricle (lower chamber) in their heart. This condition can be initially managed with a Fontan operation, but there is a risk of developing Fontan Circulatory Failure (FCF) later in life. FCF occurs when the single working heart ventricle is no longer strong enough to pump blood throughout the body. This also means the heart has difficulty supplying oxygen to keep up with the needs of the body. As a result, individuals living with FCF may have some challenges carrying out day to day activities. A heart transplant is currently the only therapeutic option for individuals living with FCF. The investigators are conducting this trial to determine whether a medication called empagliflozin can help these people have a better quality of life.
Phase 3
Waitlist Available
University Health NetworkBoehringer Ingelheim
Image of University of Utah Hospital in Salt Lake City, United States.

Bumetanide vs. Furosemide for Liver Cirrhosis

18+
All Sexes
Salt Lake City, UT
Patients with cirrhosis are frequently hospitalized due to an acute decompensation of their liver disease including bleeding, jaundice, encephalopathy, and volume overload. Volume overload is associated with increased mortality from acute hypoxic respiratory failure, hemorrhage from esophageal varices, and spontaneous bacterial peritonitis. Clinical practice guidelines describe sodium restriction and diuretics as first-line treatment, combined with regular body weight monitoring to assess response. In patients with suboptimal response to furosemide, alternative loop diuretics like torsemide or bumetanide may improve natriuresis. Bumetanide has a theoretic advantage over furosemide due to its more rapid and complete intestinal absorption, combined with a prolonged half-life in patients with hepatic dysfunction. In this pragmatic study, the aim is to compare the efficacy of diuresis with bumetanide versus furosemide among hospitalized patients with cirrhosis.
Phase 3
Waitlist Available
University of Utah HospitalStacy A Johnson, MD
Image of Columbia University Irving Medical Center in New York, United States.

Droxidopa for Liver Cirrhosis and Acute Kidney Injury

18 - 70
All Sexes
New York, NY
This study tests whether a medication called droxidopa can help improve blood flow to the kidneys in people with liver cirrhosis who develop kidney problems while in the hospital. When someone with cirrhosis experiences kidney injury, having better blood pressure can help their kidneys recover. Droxidopa is an oral medication that may help raise blood pressure without requiring intensive care or invasive treatments. The study will compare droxidopa to a placebo (inactive pill) in 75 people hospitalized with cirrhosis and kidney injury. Participants will take either droxidopa or placebo pills for 28 days and be monitored for an additional 30 days. Researchers will measure changes in blood pressure and kidney function to determine if droxidopa is effective and safe for these patients. This research could identify a new treatment option for a serious complication of liver disease.
Phase 2
Recruiting
Columbia University Irving Medical CenterGiuseppe Cullaro, MD, MAS
Have you considered Edecrin clinical trials? We made a collection of clinical trials featuring Edecrin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security